As permitted by Section 2(a) of the Series H Warrants to Purchase Common Stock (the ?Series H Warrants?), on Friday, May 13, 2016, the board of directors of the Company approved a voluntary reduction of the exercise price for 7.5 million of the outstanding Series H Warrants, from the current exercise price of $0.75 per share of common stock to $0.30 per share of common stock, for the remaining term of these warrants. Except for the reduction in exercise price, the terms of these Series H Warrants remain unchanged.
Serie-H, wo auch immer die her kommen. Oder erst noch angeboten werden?????
Aber der kompl. Ausübungspreis verringert sich für die 7,5 Mio Warrants von 5,6 auf 2,25 Mio$. Die Frage ist jetzt noch nach dem Bezugsverh. Aktie/ Warrant. Dann kennt man den Ausübungspreis je Aktie.
Habe mal was gefunden.
Pursuant to this prospectus supplement and the accompanying prospectus, we are offering for sale 3,721,429 Series C units, with each Series C unit consisting of one share of our common stock, one Series F warrant to purchase one share of our common stock and two Series H warrants, each to purchase one share of our common stock. Each full Series F warrant gives the warrant holder the right to purchase one share of our common stock. Each full Series H warrant entitles the holder thereof to purchase one share of our common stock. Each Series C unit will be sold at a negotiated price of $0.35 per unit. The Series C units will not be issued or certificated. The shares of common stock and the warrants are immediately separable and will be issued separately, but will be purchased together in this offering.
We are also offering to those purchasers whose purchase of Series C units in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of Series C units that would otherwise result in ownership in excess of 4.99% of our outstanding common stock, 6,571,429 Series D units. Each Series D unit will consist of one pre-funded Series G warrant to purchase one share of our common stock, one Series F warrant to purchase one share of our common stock and two Series H warrants, each to purchase one share of our common stock. Each full pre-funded Series G warrant entitles the holder thereof to purchase one share of our common stock. Each Series D unit will be sold at a negotiated price of $0.34 per unit. The Series D units will not be issued or certificated. The warrants are immediately separable and will be issued separately, but will be purchased together in this offering.
The shares of our common stock issuable from time to time upon exercise of the Series F warrants, the pre-funded Series G warrants and the Series H warrants are also being offered pursuant to this prospectus supplement and the accompanying prospectus.
The Series F warrants will be exercisable during the period commencing on October 1, 2016 and ending on April 1, 2021, the expiration date of the Series F warrants, at an initial exercise price of $0.35 per share of common stock. The pre-funded Series G warrants will be exercisable during the period commencing on the date of original issuance and ending on April 1, 2017, the expiration date of the pre-funded Series G warrants, at an exercise price of $0.35 per share of common stock. The exercise price of $0.35 per share will be pre-paid, except for a nominal exercise price of $0.01 per share, upon issuance of the pre-funded Series G warrants and, consequently, no additional payment or other consideration (other than the nominal exercise price of $0.01 per share) will be required to be delivered to us by the holder upon exercise. The Series H warrants will be exercisable during the period commencing on the original issuance date and ending on October 1, 2016, the expiration date of the Series H warrants, at an initial exercise price of $0.75 per share of common stock. See ?Description of Our Common Stock? and ?Description of Our Warrants? for more information on the securities offered hereby.
Our common stock is traded on the NASDAQ Capital Market under the symbol ?GEVO.? On March 28, 2016, the last reported sale price of our common stock on the NASDAQ Capital Market was $0.46 per share. The warrants are not and will not be listed for trading on the NASDAQ Capital Market, or any other securities exchange.
http://secfilings.nasdaq.com/...INC.&FormType=424B5&View=html
Um Aussagen zu treffen habe ich mich zu wenig eingelesen.
|
Thread abonnieren
ETF-Sparplan